Levoleucovorin

DRUG13 trials

Sponsors

Unicancer, Children's Oncology Group, Fujian Cancer Hospital, Asan Medical Center, Merck Sharp & Dohme LLC

Conditions

Acute Leukemia of Ambiguous LineageAcute Lymphoblastic LeukemiaB Acute Lymphoblastic LeukemiaColonic NeoplasmsColorectal NeoplasmsEsophageal AdenocarcinomaEsophageal Adenocarcinoma (EAC)Esophageal Cancer

Phase 1

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

RecruitingNCT06469944

Merck Sharp & Dohme LLCEsophageal Cancer, Esophageal Neoplasms, Gastroesophageal Adenocarcinoma +1

Start: 2024-09-20End: 2029-09-12Target: 160Updated: 2026-10-07

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

RecruitingNCT06780111

Merck Sharp & Dohme LLCEsophageal Squamous Cell Carcinoma

Start: 2025-07-30End: 2032-01-04Target: 298Updated: 2026-10-27

Phase 2

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

WithdrawnNCT03222089

Fujian Cancer HospitalMetastatic Colorectal Cancer

Start: 2017-07-20End: 2020-07-20Updated: 2018-03-27

Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

CompletedNCT03698461

Asan Medical CenterColonic Neoplasms, Colorectal Neoplasms, Neoplasm Metastasis +1

Start: 2019-05-15End: 2023-10-24Updated: 2024-01-31

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Active, not recruitingNCT05945823

Taiho Oncology, Inc.Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer +2

Start: 2023-07-13End: 2027-01-01Updated: 2026-09-01

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

RecruitingNCT06317662

National Cancer Institute (NCI)Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia

Start: 2025-06-05End: 2028-12-31Target: 153Updated: 2026-10-27

LOGICAN : Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin ± nivolumab versus FOLFOX ± nivolumab in patients with HER2 negative locally advanced, recurrent or metastatic gastric, oesophageal or junctional adenocarcinoma

RecruitingCTIS2024-512999-35-00

Unicanceroesophagus or gastroesophageal junction adenocarcinoma, Patients with HER 2 negative locally advanced, recurrent or metastatic gastric

Start: 2023-06-23Target: 118Updated: 2025-12-11

COLIBRI-GI_Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/ proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases

Not yet recruitingCTIS2025-524215-36-00

UnicancerPatients with non resectable pMMR/MSS BRAF wt mCRC, without liver metastasis in the secondline setting after first-line FOLFOX-based chemotherapy

Target: 130Updated: 2026-09-11

Phase 3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active, not recruitingNCT03007147

Children's Oncology GroupAcute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia +1

Start: 2017-08-08End: 2034-09-30Updated: 2026-10-05

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

CompletedNCT04210115

Merck Sharp & Dohme LLCEsophageal Adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)

Start: 2020-02-28End: 2026-06-23Updated: 2026-07-22

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

TerminatedNCT04949256

Merck Sharp & Dohme LLCMetastatic Esophageal Squamous Cell Carcinoma

Start: 2021-07-28End: 2026-05-20Updated: 2026-08-21

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

RecruitingNCT05253651

Seagen, a wholly owned subsidiary of PfizerColorectal Neoplasms

Start: 2022-10-24End: 2030-07-03Target: 400Updated: 2026-07-22

A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma

Not yet recruitingNCT07818070

Ono Pharmaceutical Co., Ltd.Esophageal Adenocarcinoma, Esophagogastric Junction Cancer, Gastric Cancer

Start: 2027-02-01End: 2031-01-01Target: 600Updated: 2026-09-14

Related Papers

Dynamics of tumor ecosystems and microbiome in response to neoadjuvant ABFOLFOX treatment in patients with unresectable colorectal cancer with liver metastasis

Genome Medicine2026-05-30

Increased incidence of delayed methotrexate elimination in pediatric patients with Philadelphia-chromosome positive (Ph+) or ABL-class fusion positive (ABL-Class) acute lymphoblastic leukemia treated with imatinib: Results of a retrospective cohort study by the italian association of pediatric hematology-oncology (AIEOP)

Blood2025-11-03

KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC).

Journal of Clinical Oncology2025-05-28

KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma.

Journal of Clinical Oncology2025-01-27

MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer

Future Oncology2024-12-2610 citations

Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer

Clinical Pharmacokinetics2024-10-012 citations

Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).

Journal of Clinical Oncology2024-06-013 citations

LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma

Future Oncology2024-05-024 citations

Results from the phase 1b/2 SGNTUC-024 study: Assessment of tucatinib, trastuzumab, and FOLFOX for HER2+ GI cancers.

Journal of Clinical Oncology2024-01-202 citations

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.

Journal of Clinical Oncology2023-06-012 citations

Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer

Frontiers in Immunology2023-05-1914 citations

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.

Journal of Clinical Oncology2023-01-2418 citations

Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial

Frontiers in Oncology2022-07-1329 citations

First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress.

Journal of Clinical Oncology2022-06-012 citations

LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma.

Journal of Clinical Oncology2022-01-195 citations

KEYNOTE-975 Study Design: a Phase III Study of Definitive Chemoradiotherapy Plus Pembrolizumab in Patients with Esophageal Carcinoma

Future Oncology2021-02-03121 citations